Milestones in Drug Therapy
The First Once-Daily Long-Acting Beta2 Agonist for COPD
Milestones in Drug Therapy
The First Once-Daily Long-Acting Beta2 Agonist for COPD
Here is a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for treating COPD. Covers design and pre-clinical pharmacology of the molecule, early clinical development, efficacy studies and more.
Levertijd circa 6 tot 12 dagen geen retour recht
Here is a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled 2 agonist for treating COPD. Covers design and pre-clinical pharmacology of the molecule, early clinical development, efficacy studies and more.
